Feedback / Questions
prezalumab (AMG 557) - Amgen, AstraZeneca
AstraZeneca: Q1 FY 2016 Update
(AstraZeneca)
-
Apr 30, 2016 -
Anticipated top-line results from P1 trial (NCT01683695) in SLE and lupus related inflammatory arthritis in Q2 2016
Anticipated P1 data
•
Immunology
https://www.astrazeneca.com/content/dam/az/press-releases/2016/Clinical_trials_appendix_Q1_2016_update.pdf
Apr 30, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious